Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?
Monoclonal Antibodies in Immunodiagnosis & Immunotherapy · 2023
DOI: 10.1089/mab.2022.0026 ↗Kurz gefasst
Fallbericht in der Zeitschrift Monoclonal Antibodies in Immunodiagnosis & Immunotherapy, 2023. Verfasst von Alessia Marcellino und 12 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics and Neonatology Unit, Maternal-Child Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy. Hauptthemen laut MEDLINE: Familial Hypophosphatemic Rickets. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
X-linked hypophosphatemia is a genetic condition that leads to fibroblast-growth-factor 23 (FGF23) increase, causing phosphate renal wasting. Since 2018, burosumab, an anti-FGF23 antibody, has been used for this disease with different dosage in children and adults. We report the case of burosumab administration every 2 weeks, as usually done in children. We retrospectively evaluated parathormone (PTH), alkaline phosphatase, serum phosphate, tubular reabsorption of phosphate (TRP), and 25OH vitamin D every 2 weeks in a 29-year-old man with nephrocalcinosis and tertiary hyperparathyroidism who did not respond to standard treatment with burosumab nor to maximum dosage and was treated with burosumab 90 mg every 2 weeks. His serum phosphate and TRP increased with this regimen compared with 4 weeks frequency (respectively 1.74 ± 0.26 mg/dL vs. 2.3 ± 0.19 mg/dL [ p 0.0004] and 71.3% ± 4.8% vs. 83.9% ± 7.9% [ p 0.01]) with decrease in PTH (183 ± 24.7 pg/mL vs. 109 ± 12.2 pg/mL [ p 0.04]). Burosumab may be a good choice in adult patients with X-linked hypophosphatemia; new data are needed regarding the increase in dosage and/or frequency of administration as usually done in children, to achieve disease control.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pediatrics and Neonatology Unit, Maternal-Child Department, Santa Maria Goretti Hospital, Sapienza University of Rome, Latina, Italy.
- Department of Molecular Medicine, Policlinico Umberto I, Sapienza University of Rome, Rome, Italy.
- Department of Emergency Medicine, University of Rome La Sapienza, Roma, Lazio, Italy.
ORCID-Profile: Alessia Marcellino
Zitieren
APA
Marcellino, A., Bloise, S., Pirone, C., Brandino, G., Gizzone, P., Fraternali, R., Dilillo, A., Del Giudice, E., Martucci, V., Sanseviero, M., Rita, L. M., Ventriglia, F., & Lubrano, R. (2023). Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. https://doi.org/10.1089/mab.2022.0026
Vancouver
Marcellino A, Bloise S, Pirone C, Brandino G, Gizzone P, Fraternali R, et al. Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?. Monoclonal Antibodies in Immunodiagnosis & Immunotherapy. 2023. doi:10.1089/mab.2022.0026
BibTeX
@article{Marcellino2023,
author = {Marcellino, Alessia and Bloise, Silvia and Pirone, Carmelo and Brandino, Giulia and Gizzone, Pietro and Fraternali, Roberta and Dilillo, Anna and Del Giudice, Emanuela and Martucci, Vanessa and Sanseviero, Mariateresa and Rita, Leone Maria and Ventriglia, Flavia and Lubrano, Riccardo},
title = {Efficacy of Burosumab Every 2 Weeks in an Adult with X-Linked Hypophosphatemia: Should We Learn from Children?},
journal = {Monoclonal Antibodies in Immunodiagnosis & Immunotherapy},
year = {2023},
doi = {10.1089/mab.2022.0026}
}
EUVIMED